Intra-cellular therapies announces u.s. fda approval of caplyta® (lumateperone) for the treatment of bipolar depression in adults

Caplyta is the only fda-approved treatment for depressive episodes associated with bipolar i or ii disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate.

ITCI Ratings Summary

ITCI Quant Ranking